Zura Bio Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zura Bio Limited (ZURA)
Zura Bio's October 27, 2026 SEC filing, which included a shelf registration covering up to $700 million in securities, described tibulizumab as the Company's lead product candidate being "currently advanced" in Phase 2 clinical trials. Less than two weeks later, TibuSHIELD failed to meet...
Covered in this story
Call it yourself
No calls on $ZURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Zura Bio →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.